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Editorial 
 
Focusing on cognitive morbidity in childhood brain tumours. 
 
In this issue, Thomas et al [1] report on a novel European collaboration involving 18 
countries that will improve the measurement and clinical utility of cognitive and psychosocial 
assessments in children and young people (CYP) who survive brain tumours.  
 
Survival rates in children treated for brain tumours have improved in recent years ranging 
from 60% to 85% for most tumours [2], thus raising considerations on the quality of survival (QoS) 
and the need for standardized methods to address the high level of psychosocial morbidity 
presented by survivors. The paper explains the logic, challenges and the outcome of a 10-year 
discussion between QoS representatives of the European Society of Paediatric Oncology- Brain 
Tumour working group to develop a cognitive assessment battery that is both feasible and reliable, 
and could facilitate international data set acquisition and comparison. The Core-Plus model, as it is 
named, is constituted by a core and supplementary data set for all CYP in Europe with 
ependymomas.  
 
Modern treatment approaches have resulted in a lowering of the age of focal irradiation 
from three years to eighteen months of age [3], despite concerns over long-term effects from 
treatments [4]. The piloting of the Core-Plus model has highlighted important issues (e.g. challenges 
of testing children aged 3 to 4 years, test availability and validity across countries), and work is under 
way to further improve the model, for example by complementing it with measurement of broader 
factors (e.g. parental factors) and developmental questionnaires.  
 
The Consensus model could facilitate successful global collaborations allowing greater 
insight into the treatment outcomes and developmental trajectories of young children treated with 
modern treatment protocols. 
 
It has been recognised for decades that cognitive impairment is an established consequence 
of surviving a brain tumour when young. Surprisingly, we remain unaware of the magnitude of the 
neurocognitive burden and consequently limited in our interventions. The issue of long-term 
sequelae has been exponentially gaining attention not only within the research community but also 
at government policy levels [5]. The paper of Thomas et al. proposes a model of 
neurodevelopmental assessment that can be consistently and uniformly adopted, thus allowing the 
comparison of studies and treatments. The reliable identification and measurement of 
neurocognitive outcomes will provide insights into the mechanisms whereby a brain tumour and its 
treatments affect the brain throughout development. The creation of a large dataset in childhood 
ependymomas will facilitate prediction models that stratify children at risk of consequences and 
enhance early interventions. This European consensus will strongly support the routine 
incorporation of neuropsychology assessments as key outcomes (either primary or secondary) in a 
variety of clinical trials. The adoption of the proposed Core-plus protocol will allow significant 
insights to be formed in terms of neurodevelopmental sequelae, and the need for educational and 
psychosocial interventions. This model could also be adopted beyond brain tumour research to 
many other areas of paediatric neurology where there is a high burden of neuropsychological and 
neurodevelopmental consequences. 
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